Effect of pentoxifylline on anaemia control in haemodialysis patients: Retrospective observational case-control study;Efecto de la pentoxifilina en la anemia de pacientes en hemodiálisis: Estudio retrospectivo observacional de casos y controles

Nefrologia

Volumn 33, Issue 4, 2013, Pages 524-531

  Mora Gutiérrez, José M ^a   Ferrer Nadal, Asunción ^a   García Fernández, Nuria ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Anaemia; Hemodialysis; Pentoxifylline8Inflammation

Indexed keywords

ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE;

ANEMIA; ARTICLE; CASE CONTROL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY;

ANEMIA; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 84882945925     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2013.Apr.11654     Document Type: Article

References (29)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162(12):1401-8.
2. Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M. Renal anemia of inflammation: the name is self-explanatory. Blood Purif 2011;32:220-5.
3. Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010;29:1-12.
4. Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia management in hemodialysis patients. Hemodial Int 2009;13:222-34.
5. Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 1999;47:204-11.
6. Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1984;4:297-307.
7. González-Espinoza L, Rojas-Campos E, Medina-Pérez M, Peña-Quintero P, GÓmez-Navarro B, Alfonso M, et al. Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. Nephrol Dial Transplant 2012;27:2023-8.
8. Cooper A, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure. J Am Soc Nephrol 2004;15:1877-82.
9. Navarro JF, Mora C, García J, Rivero A, Macía M, Gallego E, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. Scand J Urol Nephrol 1999;33(2):121-5.
10. Macdougall IC. Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients. Nephrol Dial Transplant 2004;19 Suppl 5:V73-78.
11. Mortazavi M, Seyrafian S, Taheri S, Nasiri R, Dolatkhah S, Naini AE, et al. Role of pentoxifylline in treatment of anemic patients suffering chronic hemodialysis: a randomized clinical trial. Med Arh 2012;66:84-6.
12. Watson P, Watson I, Batt R. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980;33:27-39.
13. Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol 2008;9:8.
14. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009;4:470-80.
15. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-82.
16. Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36.
17. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, De Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
18. Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995;25 Suppl 2:S80-4.
19. Benbernou N, Esnault S, Potron G, Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J Cardiovasc Pharmacol 1995;25 Suppl 2:S75-9.
20. Goicoechea M, García de Vinuesa S, Quiroga B, Verdalles U, Barraca D, Yuste C, et al. Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial. J Nephrol 2012;25:969-75.
21. Ferrari P, Mallon D, Trinder D, Olynyk JK. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) 2010;15:344-9.
22. Arosio P, Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta 2010;1800:783-92.
23. Kaysen GA. Biochemistry and biomarkers of inflamed patients: why look, what to assess. Clin J Am Soc Nephrol 2009;4 Suppl 1:S56-63.
24. Bowry SK, Gatti E. Impact of hemodialysis therapy on anemia of chronic kidney disease: the potential mechanisms. Blood Purif 2011;32:210-9.
25. Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: what is the evidence base. Nephrol Dial Transplant 2003;18 Suppl 8:viii29-35.
26. Odabas AR, Cetinkaya R, Selcuk Y, Keles S, Bilen H. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 2003;45:59-62.
27. Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY; Western Switzerland Dialysis Group. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. J Nephrol 2006;19:91-6.
28. Koc M, Dogan C, Arinsoy T, Tonbul Z, Ayli D, Cirit M, et al. Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodial Int 2011;15:366-73.
29. Granger Vallée A, Canaud B. Statins and resistance to erythropoiesis-stimulating agents: are the two associated. Nephrol Dial Transplant 2011;26:2715-6.